According to the research report, the global injectable drug delivery market size is expected to touch USD 1,223.6 Billion by 2030, from USD 611.84 Billion in 2022, growing with a significant CAGR of 9.05% from 2022 to 2030.
The injectable drug delivery report offers
a comprehensive study of the current state expected at the major drivers,
market strategies, and key vendors’ growth. The report presents energetic
visions to conclude and study the market size, market hopes, and competitive
surroundings. The research also focuses on the important achievements of the
market, research & development, and regional growth of the leading
competitors operating in the market. The current trends of the global injectable
drug delivery in conjunction with the geographical landscape of this vertical
have also been included in this report.
The report offers intricate dynamics about
different aspects of the global injectable drug delivery market, which aids
companies operating in the market in making strategic development decisions.
The study also elaborates on significant changes that are highly anticipated to
configure growth of the global injectable drug delivery during the forecast
period. It also includes a key indicator assessment that highlights growth
prospects of this market and estimates statistics related to growth of the
market in terms of value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1760
| Report Coverage | Details |
| Market Size by 2030 | USD 1,223.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 9.05% |
| Largest Market | North America |
| Fastest Growing Market | Europe |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Distribution Channel, Facility of Use, Geography |
This study covers a detailed segmentation
of the global injectable drug delivery market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global injectable drug delivery market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Becton
- Dickinson and Company
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Baxter International, Inc.
- Sandoz
- Terumo
- Schott AG
- Gerresheimer
- Ypsomed
- Bespak
- B. Braun Melsungen
Market Segmentation
- Devices
- Conventional Injectables
- Pre-Filled Syringes
- Auto-Injectors
- Pen-Injectors
- Formulations
By Formulation Packaging
- Ampules
- Vials
- Cartridges
- Bottles
By Therapeutic Application
- Auto-immune diseases
- Hormonal Disorders
- Orphan Diseases
- Oncology
- Others
By Usage Pattern
- Curative Care
- Immunization
- Other
By Site of Administration
- Skin
- Circulatory/Musculoskeletal
- Organs
- Central Nervous System
By Distribution Channel
- Hospitals & Clinics
- Retail Pharmacy Stores
- Others
By Facility of Use
- Hospitals & Clinics
- Home Care Settings
- Other
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global injectable drug delivery report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global injectable drug delivery market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Injectable Drugs Delivery Market, By Type
7.1. Injectable Drugs Delivery Market, by Type, 2022-2030
7.1.1. Devices
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Formulations
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Injectable Drugs Delivery Market, By Formulation Packaging
8.1. Injectable Drugs Delivery Market, by Formulation Packaging, 2022-2030
8.1.1. Ampules
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Vials
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Cartridges
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.3. Bottles
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Injectable Drugs Delivery Market, By Therapeutic Application
9.1. Injectable Drugs Delivery Market, by Therapeutic Application, 2022-2030
9.1.1. Auto-immune diseases
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Hormonal Disorders
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Orphan Diseases
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Oncology
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Other Therapeutic Applications
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Injectable Drugs Delivery Market, By Usage Pattern
10.1. Injectable Drugs Delivery Market, by Usage Pattern, 2022-2030
10.1.1. Curative Care
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Immunization
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Other Usage Pattern
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Injectable Drugs Delivery Market, By Site of Administration
11.1. Injectable Drugs Delivery Market, by Site of Administration, 2022-2030
11.1.1. Skin
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Circulatory/Musculoskeletal
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Organs
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Central Nervous System
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Injectable Drugs Delivery Market, By Distribution Channel
12.1. Injectable Drugs Delivery Market, by Distribution Channel, 2022-2030
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Retail Pharmacy Stores
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Injectable Drugs Delivery Market, By Facility of Use
13.1. Injectable Drugs Delivery Market, by Facility of Use, 2022-2030
13.1.1. Hospitals & Clinics
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Home Care Settings
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.2. Other Facilities of Use
13.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Injectable Drugs Delivery Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.1.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.1.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.1.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.1.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.1.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.1.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.1.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.1.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.1.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.10.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.10.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.11.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.11.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.10.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.10.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.11.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.11.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.10.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.10.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.11.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.11.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.5.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.5.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.5.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.5.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.5.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.5.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.5.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 15. Company Profiles
15.1. Becton
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Dickinson and Company
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Pfizer Inc.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Teva Pharmaceuticals Industries Ltd.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Eli Lilly and Company
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Baxter International, Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Sandoz
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Terumo
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Schott AG
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Gerresheimer
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments